ClinicalTrials.gg
RecruitingNCT06894095DAILYUpdated Oct 16, 2026

Dongzong Cardiovascular Bio-imaging Registry Study

An observational study in Cardiovascular Diseases, Multi-omics and Living Environments, sponsored by Jinling Hospital, China. Recruiting at 3 sites in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Jinling Hospital, China · Observational

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 5 months later.
Updated Oct 16, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50,000
Ages
18 Years and older
Sex
All
01

Study summary

The DAILY project is a large-scale, multicenter, prospective initiative designed to establish a comprehensive bio-imaging database that integrates multidimensional data, including living environments, psychosocial and cognitive assessments, psychosocial and cognitive assessments, panvascular and body imaging (fundus, carotid artery, chest, abdomen, and heart), electrocardiograms, multi-omics profiles, clinical medication and surgical records, and health outcomes. Leveraging this extensive, multiscale dataset, the project aims to elucidate the intricate interplay between genetic biology and environmental factors in driving downstream biological alterations, thereby shaping lung and cardiovascular structural and functional phenotypes, and ultimately influencing the onset and progression of cardiovascular diseases (CVD). Through a systematic exploration and understanding of this complex network, the project seeks to identify critical intervention points and develop innovative strategies for the prevention and management of CVD.

Read the detailed description

Cardiovascular diseases (CVD) are the leading cause of global mortality, representing a major public health challenge that threatens life and health both presently and in the foreseeable future. The reduction of modifiable risk factors remains a powerful and essential strategy, however, the application of clinical risk scores has demonstrated limited efficacy in significantly reducing cardiovascular events. In recent years, the emergence of multi-omics has provided novel insights into the prevention and management of CVD, offering opportunities to deeply understand its drivers at the genetic and biological levels. Nevertheless, the clinical utility and widespread adoption of these approaches face significant challenges, primarily due to two critical factors: First, multi-omics datasets, particularly GWAS datasets, exhibit a pronounced Eurocentric bias; second, the vast array of multi-omics indicators cannot be effectively integrated with living environments and diseases to construct a comprehensive biological network, thereby hindering the deciphering of key biological pathways and biomarkers for clinical translation. To address these limitations, we propose leveraging modern imaging technologies as an "intermediate bridge", because when critical biological pathways are triggered by genes, environmental factors, or their interactions, the earliest manifestations are impairments in cardiac and pulmonary structure and function (intermediate phenotypes). Accordingly, the DAILY project aims to enroll 50,000 participants across China, stratified by economic levels, geography, and living environments, to establish a high-quality bio-imaging database. This database will encompass: (1) panvascular and whole-body imaging and electrophysiology-related phenotypes, including fundus OCT, carotid ultrasound, chest and abdominal CT, and cardiac CT, along with electrocardiogram examinations; (2) extensive multi-omics indicators, particularly genomics and downstream transcriptomics, proteomics, and metabolomics; (3) comprehensive living environments, psychological and cognitive date, and longitudinal health outcome; and (4) clinical medication and surgical records, along with other detailed clinical information.

Currently, there is a lack of a high-quality bio-imaging data platform based on the Chinese population to construct a complete pathway from genes/environment to disease, thereby enabling the development of promising strategies for CVD prevention and management.

02

Conditions studied

  • Cardiovascular Diseases
  • Multi-omics
  • Living Environments
  • Pulmonary-cardiovascular Imaging
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 50,000 is above the median of 534 across 1,577 observational studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Jinling Hospital, China is the lead sponsor of 131 studies on the registry; 35 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Consecutively enrolled individuals scheduled for coronary CTA, including those with known or suspected coronary artery disease (CAD) or individuals undergoing screening

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years
  • Coronary CT angiography performed
  • acquired

Exclusion criteria

Exclusion Criteria:

  • Unable to complete the follow-up
  • Serious chronic kidney disease (\< 30 ml/min/1.73 m2)
  • Serious liver disease or dysfunction (chronic active hepatitis and cirrhosis, or (AST) or alanine transaminase (ALT) > 3 times the )
  • Not appropriate to be tested due to birth planning, allergies, acute thyroid storm, etc.
  • Suspected or known infectious diseases, such as virus (HBV), (HIV)/acquired immunodeficiency syndrome (AIDS), and Treponema pallidum (syphilis), etc.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Major adverse cardiovascular events

    Occurrence of major adverse cardiovascular events at prespecified follow-up ( once a year till the thirty year), defined as a composite of all-cause death, non-fatal myocardial infarction, unplanned revascularization , and hospitalization for unstable angina. Death cases consist of cardiovascular death, non-cardiovascular death, and undetermined cause of death.

    Time frame: Once a year until the tenth year

Secondary outcomes

  1. Invasive coronary angiography

    Including invasive coronary angiography, diagnostic invasive coronary angiography with revascularization, and invasive coronary angiography without obstructive coronary disease (\> 70% or \>50% diameter stenosis)

    Time frame: Once a year until the tenth year

  2. Coronary revascularization

    Coronary artery bypass grafting, percutaneous coronary interventions

    Time frame: Once a year until the tenth year

  3. Cardiovascular death, heart failure, atrial fibrillation, non-fatal MI, non-fatal stroke, unplanned revascularization, hospitalization for unstable angina

    Cardiovascular death, heart failure, atrial fibrillation, non-fatal MI, non-fatal stroke, unplanned revascularization, hospitalization for unstable angina

    Time frame: Once a year until the tenth year

  4. Coronary plaque progression, regression, formation

    Changes in the degree of coronary artery stenosis or plaque volume, or coronary plaque formation, or the volume, characteristics, and composition of high-risk plaques will be observed in participants with serial coronary CTA

    Time frame: Once every two years at least, until the tenth year

  5. Changes in functional small airways, pulmonary small vessels and emphysema volume

    Patients undergoing serial chest CT scans were followed up to monitor changes in quantitative CT parameters, including emphysema volume, functional small airway volume, normal lung parenchyma volume and its percentage of total lung volume, as well as quantitative pulmonary small vessel metrics: the number of pulmonary vessels located at 6, 9, 12, 15, 18, 21, and 24 mm from the pleura across the entire lung, and the number of small vessels with a cross-sectional area less than 5 mm², or other relevant parameters

    Time frame: Once every two years at least, until the tenth year

  6. Emerging disease, regression or progression of established disease

    Emerging diseases across various systems, such as metabolic disorders (e.g., hypertension, hyperlipidemia, hyperglycemia), cardiovascular diseases (e.g., hypertrophic cardiomyopathy, myocarditis), peripheral vascular diseases (e.g., deep vein thrombosis, arteritis), respiratory diseases (e.g., COPD, pulmonary hypertension), neurological disorders (e.g., dementia, Alzheimer's disease), malignancies (e.g., lung cancer, breast cancer), and diseases of other systems, will be documented. Additionally, the progression or regression of established disease will be recorded, for example, the development of diabetic retinopathy following the worsening of diabetes or the regression of impaired glucose tolerance, as well as the early surgical treatment of lung cancer or its recurrence in advanced stages.

    Time frame: Once a year until the tenth year

  7. Medication adjustment

    Medication adjustment includes the increase or decrease of the drug dose and the new addition or discontinuation of medications after CCTA examination.

    Time frame: Once a year until the tenth year

  8. Medication regularly

    Taking medication regularly defined as the total number of days within the final month of a year during which established medication is taken (including Antiplatelet agents, Antihypertensive agents, Hypoglycemic agents, Lipid-lowering agents, Anti-inflammatory agents and and other agents).

    Time frame: once a year till the tenth year

  9. Smoking, alcohol consumption, dietary habits, physical activity, symptoms, life quality

    A questionnaire-based follow-up that will mainly focus on smoking, alcohol consumption, dietary habits, physical activity, symptoms, and life quality (EQ-5D)

    Time frame: Once every five years until the tenth year

  10. Anxiety and cognition

    A questionnaire-based follow-up that will mainly focus on anxiety and cognition

    Time frame: Once every five years until the tenth year

  11. Adverse reactions to iodinated contrast agents

    Acute adverse and late adverse reactions to iodinated contrast agents

    Time frame: Within 1 hour and between 1 hour to 1 week after after contrast agent injection

07

Study locations

3 of 3 sites recruiting
  • Longjiang Zhang
    Nanjing, Jiangsu 210002, China
    Recruiting
  • Longjiang Zhang
    Suqian, Jiangsu 223800, China
    Recruiting
  • Longjiang Zhang
    Zhenjiang, Jiangsu 212001, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Mar 2028, 58 months after the start.

Of 583 non-industry observational studies under Cardiovascular Diseases, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 196. This study's planned 58 months is below that.

Counting every sponsor, half of 667 studies reached it within 62 months; a quarter within 24 and three quarters within 192.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2025
First posted
Mar 25, 2025
StartActual
May 24, 2023
Primary completionEst.
Mar 31, 2028
CompletionEst.
May 31, 2038
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 China)
  • Longjiang Zhang · Suqian, China
  • Longjiang Zhang · Zhenjiang, China
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    2 sites added
    Show 2 added (2 China)
    • Longjiang Zhang · Suqian, China
    • Longjiang Zhang · Zhenjiang, China
    + 4 other changes: identifiers, verification date, oversight details and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06894095
Responsible party
Zhang longjiang,MD (Principal Investigator (PI): Zhang Longjiang; Co-PI: Tang Chunxiang, Jinling Hospital, China) — Principal investigator
First posted
Mar 25, 2025
Start date
May 24, 2023
Primary completion
Mar 31, 2028 (estimated)
Completion
May 31, 2038 (estimated)
Last update
Oct 16, 2026

Study contacts

Longjiang Zhang, MD
Contact
kevinzhlj@163.com
13405833167
Chunxiang Tang, PhD
Contact
tangcx@nju.edu.cn
13814096738
Longjiang Zhang, MD
principal investigator · Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion